FDA supplement subcommittee
This article was originally published in The Tan Sheet
Executive Summary
Meeting scheduled for March 25 will evaluate "recognized scientific principles that would facilitate reaching a conclusion as to whether a particular substance is a 'metabolite' of another substance that is a 'dietary ingredient' defined in the [FD&C Act] and, therefore, is itself a dietary ingredient," according to March 5 Federal Register notice. FDA says the act currently "is ambiguous...as to what substances are, or are not, metabolites of other substances," which makes it "often difficult to determine whether a particular substance...can be marketed as [a] dietary supplement." Meeting will be held at Holiday Inn, 10,000 Baltimore Ave., College Park, Md. Dietary Supplement Subcommittee of the Food Advisory Committee will not meet March 27-28, as reported in 1"The Tan Sheet" Feb. 10, 2003, In Brief...
You may also be interested in...
“Metabolite” DSHEA Definition Incorporates Oral Ingestion
The definition of "metabolite" established by FDA's Food Advisory/Dietary Supplement Subcommittee meets DSHEA's statutory requirements by addressing human consumption, according to panelist Eric Brass, MD/PhD, Harbor-UCLA Center for Clinical Pharmacology
NDAC meetings rescheduled
Nonprescription Drugs Advisory Committee tentative meeting dates have been rescheduled for June 12-13 and Sept. 16-17. Dietary Supplements Subcommittee tentative meeting dates still slated for March 27-28 and Sept. 22-23, as reported in 1"The Tan Sheet" Dec. 23, 2002, In Brief...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.